Mirum Pharmaceuticals, Inc. (MIRM) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, commercializing three approved medicines: LIVMARLI (maralixibat), Cholbam (cholic acid), and CTEXLI (chenodiol). The company operates as a single segment and is classified as a large accelerated filer.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Product Sales, Net | $176.2 million | $127.8 million | $336.1 million | $239.4 million |
| Net Loss | $(67.2) million | $(5.9) million | $(857.4) million | $(20.5) million |
| Loss Per Share (Basic/Diluted) | $(1.06) | $(0.12) | $(14.03) | $(0.42) |
| Operating Expenses | $218.8 million | $132.8 million | $1,168.1 million | $259.5 million |
| Cash & Investments (Unrestricted) | $561.3 million (as of June 30, 2026) | |||
| Convertible Notes Outstanding | $769.0 million principal ($750.1 million net) |
Material Changes vs. Prior Period
- Revenue Growth: Net product sales increased 38% year-over-year in Q2 and 40% year-over-year YTD, driven by higher sales of LIVMARLI (ALGS and PFIC indications) and new patient starts for Bile Acid Medicines (Cholbam and Ctexli).
- Significant One-Time Charges: The YTD net loss was heavily impacted by a $742.7 million charge for Acquired In-Process Research and Development (IPR&D). This included a $726.3 million charge related to the acquisition of Bluejay Therapeutics (brelovitug) and a $16.4 million charge for the zilurgisertib license from Incyte.
- Debt Restructuring: In May 2026, the company issued $690.0 million of 0.00% Convertible Senior Notes due 2032. Concurrently, it repurchased $237.2 million of its 2029 Notes using cash and stock, recognizing an $11.7 million debt conversion inducement expense.
- Stock-Based Compensation: YTD stock-based compensation totaled $88.0 million, including $34.7 million in accelerated expenses related to the Bluejay acquisition.
Guidance, Outlook, and Risks
- Liquidity: Management believes unrestricted cash, cash equivalents, and investments of $561.3 million are sufficient to fund operations for at least 12 months from the filing date.
- Product Pipeline:
- Brelovitug (Bluejay): Topline data from AZURE-1 and AZURE-4 trials expected in late 2026; potential BLA submission in H1 2027.
- Volixibat: FDA recommended a Phase 3 study for PSC; potential NDA submission expected in H1 2027.
- LIVMARLI: EXPAND study enrollment completed; topline data expected in Q4 2026.
- Key Risks:
- Patent Litigation: Ongoing Hatch-Waxman litigation against multiple generic manufacturers (Sandoz, Hetero, Biophore, Zydus) regarding LIVMARLI patents. Trial set for September 2028.
- Regulatory & Clinical: Risks associated with clinical trial outcomes, regulatory approvals, and potential delays in patient enrollment.
- Integration: Risks related to the successful integration of Bluejay Therapeutics and its product candidate.
Investor Verification Checklist
- Bluejay Acquisition Accounting: Verify the $726.3 million IPR&D charge and the fair value assumptions used for brelovitug.
- Debt Conversion Terms: Review the terms of the 2029 Notes conversion window (Q3 2026) and the impact of the 2032 Notes issuance on future dilution.
- Patent Litigation Status: Monitor the LIVMARLI patent litigation progress and the 30-month stay expiration date (March 2029).
- Cash Burn Rate: Assess operating cash flow usage ($273.0 million used YTD) against the $561.3 million cash balance to validate the 12-month liquidity runway.
- Revenue Recognition: Review estimates for variable consideration from distributor and partner sales (e.g., Takeda), which can cause quarterly volatility.